RETRACTED: Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway (Retracted Article. See vol 24, pg 1964, 2005)

被引:41
作者
Stoica, GE
Franke, TF
Wellstein, A
Morgan, E
Czubayko, F
List, HJ
Reiter, R
Martin, MB
Stoica, A
机构
[1] Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA
[2] Columbia Univ, Dept Pharmacol, New York, NY 10032 USA
[3] Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20007 USA
[4] Univ Marburg, Sch Med, Dept Pharmacol & Toxicol, D-35033 Marburg, Germany
关键词
estrogen receptor; HRG-beta; 1; ErbB2; Akt;
D O I
10.1038/sj.onc.1206311
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
This study examines whether the serine/threonine protein kinase, Akt, is involved in the crosstalk between the ErbB2 and estrogen receptor-alpha (ER-alpha) pathways. Treatment of MCF-7 cells with 10(-9) M heregulin-beta1 (HRG-beta) resulted in a rapid phosphorylation of Akt and a 15-fold increase in Akt activity. Akt phosphorylation was blocked by inhibitors of phosphatidylinositol 3-kinase (PI 3-K), by antiestrogens, the protein tyrosine kinase inhibitor, genistein, and by AG825, a selective ErbB2 inhibitor; but not by AG30, a selective EGFR inhibitor. Akt phosphorylation by HRG-beta1 was abrogated by an arginine to cysteine mutation (R25C) in the pleckstrin homology (PH) domain of Akt, and HRG-beta1 did not induce Akt phosphorylation in the ER-negative variant of MCF-7, MCF-7/ADR. Transient transfection of ER-alpha into these cells restored Akt phosphorylation by HRG-beta1, suggesting the requirement of ER-alpha. HRG-beta1 did not activate Akt in MCF-7 cells stably transfected with an anti-ErbB2-targeted ribozyme, further confirming a role for ErbB2. Stable transfection of the cells with a dominant negative Akt or with the R25C-Akt mutant, as well as PI 3-K inhibitors, blocked the effect of HRG-beta1 on ER-alpha expression and activity and on the growth of MCF-7 cells. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of HRG-beta1. Experiments employing selective ErbB inhibitors demonstrate that the effect of HRG-beta1 on ER-alpha expression and activity is also mediated by ErbB2 and not by EGFR, demonstrating that ErbB2 is the primary mediator of the effects of HRG-beta1 on ER-a regulation. Taken together, our data suggest that HRG-beta1, bound to the ErbB2 ErbB3 heterodimer, in the presence of membrane ER-alpha, interacts with and activates PI 3-K/Akt. Akt leads to nuclear ER-alpha phosphorylation, thereby altering its expression and transcriptional activity.
引用
收藏
页码:2073 / 2087
页数:15
相关论文
共 120 条
[61]   PURIFICATION AND CHARACTERIZATION OF A NOVEL GROWTH-FACTOR FROM HUMAN BREAST-CANCER CELLS [J].
LUPU, R ;
WELLSTEIN, A ;
SHERIDAN, J ;
ENNIS, BW ;
ZUGMAIER, G ;
KATZ, D ;
LIPPMAN, ME ;
DICKSON, RB .
BIOCHEMISTRY, 1992, 31 (32) :7330-7340
[62]   The significance of heregulin in breast cancer tumor progression and drug resistance [J].
Lupu, R ;
Cardillo, M ;
Cho, C ;
Harris, L ;
Hijazi, M ;
Perez, C ;
Rosenberg, K ;
Yang, D ;
Tang, C .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) :57-66
[63]   THE ROLE OF ERBB2-SIGNAL TRANSDUCTION PATHWAYS IN HUMAN BREAST-CANCER [J].
LUPU, R ;
LIPPMAN, ME .
BREAST CANCER RESEARCH AND TREATMENT, 1993, 27 (1-2) :83-93
[64]   Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells [J].
Márquez, DC ;
Pietras, RJ .
ONCOGENE, 2001, 20 (39) :5420-5430
[65]   A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I [J].
Martin, MB ;
Franke, TF ;
Stoica, GE ;
Chambon, P ;
Katzenellenbogen, BS ;
Stoica, BA ;
McLemore, MS ;
Olivo, SE ;
Stoica, A .
ENDOCRINOLOGY, 2000, 141 (12) :4503-4511
[66]   17-BETA-ESTRADIOL MIMICS LIGAND ACTIVITY OF THE C-ERBB2 PROTOONCOGENE PRODUCT [J].
MATSUDA, S ;
KADOWAKI, Y ;
ICHINO, M ;
AKIYAMA, T ;
TOYOSHIMA, K ;
YAMAMOTO, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10803-10807
[67]  
MCLESKEY SW, 1993, CANCER RES, V53, P2168
[68]  
Ménard S, 2000, J NATL CANCER I, V92, P943
[69]  
Mermelstein PG, 1996, J NEUROSCI, V16, P595
[70]   EFFECT OF ANTAGONISTS ON DNA-BINDING PROPERTIES OF THE HUMAN ESTROGEN-RECEPTOR IN-VITRO AND IN-VIVO [J].
METZGER, D ;
BERRY, M ;
ALI, S ;
CHAMBON, P .
MOLECULAR ENDOCRINOLOGY, 1995, 9 (05) :579-591